IRS® 19 increases specific and non-specific immunity
When spraying IRS® 19, a fine aerosol is formed that covers the nasal mucosa, which leads to the rapid development of a local immune response. Specific protection is due to locally formed antibodies of the class of secretory immunoglobulins type A (IgA), which prevent the fixation and reproduction of infectious agents on the mucosa. Nonspecific immunoprotection is manifested in an increase in the phagocytic activity of macrophages and an increase in the content of lysozyme.
For 100 ml:
Active substances:
bacterial lysates 43.27ml
Composition of bacterial lysates:
Streptococcus pneumoniae type I 1.11ml
Streptococcus pneumoniae type II 1.11ml
Streptococcus pneumoniae type III 1.11ml
Streptococcus pneumoniae type V 1.11ml
Streptococcus pneumoniae type VIII 1.11ml
Streptococcus pneumoniae type XII 1.11mg
Haemophilus influenzae type B 3.33ml
Klebsiella pneumoniae ss pneumoniae 6.66ml
Staphylococcus aureus ss aureus 9.99ml
Acinetobacter calcoaceticus 3.33ml
Moraxella catarrhalis 2.22ml
Neisseria subflava 2.22ml
Neisseria perflava 2.22ml
Streptococcus pyogenes group A 1.66ml
Streptococcus dysgalactiae group C 1.66ml
Enterococcus faecium 0.83ml
Enterococcus faecalis 0.83ml
Streptococcus group G 1.66ml
Excipients: Glycine 4.25g; Sodium merthiolate not more than 1.2 mg; Flavor based on nerol** 12.50 mg; Purified water up to 100 ml.
** Nerol based flavor composition: linalol, alpha-terpineol, geraniol, methyl anthranilate, limonene, geranyl acetate, linalyl acetate, diethylene glycol monoethyl ether, phenylethyl alcohol.
The drug is used intranasally by aerosol administration of 1 dose (1 dose = 1 short press of the spray gun).
- in order to prevent adults and children from 3 months, 1 dose of the drug in each nasal passage 2 times a day for 2 weeks (it is recommended to start a course of treatment 2-3 weeks before the expected rise in incidence);
- for the treatment of acute and chronic diseases of the upper respiratory tract and bronchi:
- children from 3 months to 3 years, one dose of the drug in each nasal passage 2 times a day, after preliminary release from the mucous discharge, until the symptoms of infection disappear.
- children over 3 years of age and adults, one dose of the drug in each nasal passage from 2 to 5 times a day until the symptoms of infection disappear;
- to restore local immunity for children and adults after influenza and other respiratory viral infections, 1 dose of the drug in each nasal passage 2 times a day for 2 weeks;
- in preparation for a planned surgical intervention and in the postoperative period for adults and children, 1 dose of the drug in each nasal passage 2 times a day for 2 weeks (it is recommended to start the course of treatment 1 week before the planned surgical intervention).
At the beginning of treatment, reactions such as sneezing and increased nasal discharge may occur. As a rule, they are of short duration. If these reactions take a severe course, the frequency of administration of the drug should be reduced or it should be canceled.
Very important! The device functions correctly only under the following conditions:
Put the nozzle on the bottle, properly center it and gently, without force, press it.
The device is now ready for use.
WHEN SPRAYING THE MEDICINE, KEEP THE BOTTLE IN A VERTICAL POSITION AND DO NOT tilt your head back.
If you tilt the bottle while spraying, the propellant will flow out in a few seconds and the device will become unusable.
With regular use of the drug, the nozzle is not recommended to be removed.
If the drug is left for a long time without use, a drop of liquid may evaporate and the resulting crystals will clog the outlet of the nozzle. This phenomenon occurs most often when the nozzle is removed and placed in the package with the top end down next to the bottle, without first washing and drying it. If the nozzle becomes clogged, press it several times to allow the liquid to pass under the influence of excess pressure. If this does not help, dip the nozzle in warm water for a few minutes.
